• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对取代苯甲脒肟的电化学和mARC催化的酶促还原:前药概念“用脒肟代替脒”的影响。

Electrochemical and mARC-catalyzed enzymatic reduction of para-substituted benzamidoximes: consequences for the prodrug concept "amidoximes instead of amidines".

作者信息

Bauch Eva, Reichmann Debora, Mendel Ralf-Rainer, Bittner Florian, Manke Anne-Marie, Kurz Philipp, Girreser Ulrich, Havemeyer Antje, Clement Bernd

机构信息

Department of Pharmaceutical and Medicinal Chemistry, Christian Albrechts University Kiel, Gutenbergstraße 76, 24118 Kiel (Germany).

出版信息

ChemMedChem. 2015 Feb;10(2):360-7. doi: 10.1002/cmdc.201402437. Epub 2014 Dec 15.

DOI:10.1002/cmdc.201402437
PMID:25512261
Abstract

The mitochondrial amidoxime reducing component (mARC) activates amidoxime prodrugs by reduction to the corresponding amidine drugs. This study analyzes relationships between the chemical structure of the prodrug and its metabolic activation and compares its enzyme-mediated vs. electrochemical reduction. The enzyme kinetic parameters KM and Vmax for the N-reduction of ten para-substituted derivatives of the model compound benzamidoxime were determined by incubation with recombinant proteins and subcellular fractions from pig liver followed by quantification of the metabolites by HPLC. A clear influence of the substituents at position 4 on the chemical properties of the amidoxime function was confirmed by correlation analyses of (1) H NMR chemical shifts and the redox potentials of the 4-substituted benzamidoximes with Hammett's σ. However, no clear relationship between the kinetic parameters for the enzymatic reduction and Hammett's σ or the lipophilicity could be found. It is thus concluded that these properties as well as the redox potential of the amidoxime can be largely ignored during the development of new amidoxime prodrugs, at least regarding prodrug activation.

摘要

线粒体偕胺肟还原成分(mARC)通过将偕胺肟前药还原为相应的脒类药物来激活它们。本研究分析了前药的化学结构与其代谢活化之间的关系,并比较了其酶介导的还原与电化学还原。通过与重组蛋白和猪肝亚细胞组分孵育,然后用高效液相色谱法对代谢物进行定量,测定了模型化合物苯甲偕胺肟的十种对位取代衍生物N-还原的酶动力学参数KM和Vmax。通过对(1)1H NMR化学位移以及4-取代苯甲偕胺肟的氧化还原电位与哈米特σ值进行相关分析,证实了4位取代基对偕胺肟官能团化学性质有明显影响。然而,未发现酶促还原的动力学参数与哈米特σ值或亲脂性之间存在明确关系。因此得出结论,在开发新的偕胺肟前药时,至少就前药活化而言,这些性质以及偕胺肟的氧化还原电位在很大程度上可以忽略不计。

相似文献

1
Electrochemical and mARC-catalyzed enzymatic reduction of para-substituted benzamidoximes: consequences for the prodrug concept "amidoximes instead of amidines".对取代苯甲脒肟的电化学和mARC催化的酶促还原:前药概念“用脒肟代替脒”的影响。
ChemMedChem. 2015 Feb;10(2):360-7. doi: 10.1002/cmdc.201402437. Epub 2014 Dec 15.
2
The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.第四种含钼酶mARC:克隆及参与N-羟基化前药的激活
J Med Chem. 2008 Dec 25;51(24):8173-7. doi: 10.1021/jm8010417.
3
Synthesis and biological evaluation of L-valine-amidoximeesters as double prodrugs of amidines.L-缬氨酸酰胺肟酯的合成及作为脒类双重前药的生物评价。
Bioorg Med Chem. 2011 Mar 15;19(6):1907-14. doi: 10.1016/j.bmc.2011.01.066. Epub 2011 Feb 3.
4
Reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC.含钼酶 mARC 还原 N-羟磺酰胺类化合物,包括 N-羟伐地考昔。
Drug Metab Dispos. 2010 Nov;38(11):1917-21. doi: 10.1124/dmd.110.032813. Epub 2010 Aug 10.
5
Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid).N-羟基化前药苯甲脒肟、胍诺苄和Ro 48-3656([[1-[(2s)-2-[[4-[(羟基氨基)亚氨基甲基]苯甲酰基]氨基]-1-氧代丙基]-4-哌啶基]氧基]-乙酸)的肝脏、肝外、微粒体和线粒体活化作用
Drug Metab Dispos. 2005 Nov;33(11):1740-7. doi: 10.1124/dmd.105.005249. Epub 2005 Aug 23.
6
Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme.将线粒体苯甲脒肟前药转化系统中缺失的成分鉴定为一种新型钼酶。
J Biol Chem. 2006 Nov 17;281(46):34796-802. doi: 10.1074/jbc.M607697200. Epub 2006 Sep 13.
7
Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC).线粒体偕胺肟还原成分(mARC)对磺胺甲恶唑羟胺(SMX-HA)的还原作用。
Chem Res Toxicol. 2014 Oct 20;27(10):1687-95. doi: 10.1021/tx500174u. Epub 2014 Sep 18.
8
The fourth mammalian molybdenum enzyme mARC: current state of research.第四种哺乳动物钼酶 mARC:研究现状。
Drug Metab Rev. 2011 Nov;43(4):524-39. doi: 10.3109/03602532.2011.608682. Epub 2011 Sep 26.
9
Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.新型口服活性直接凝血酶抑制剂希美加群(一种偕胺肟和酯前药)的体外生物转化特性研究
Drug Metab Dispos. 2003 May;31(5):645-51. doi: 10.1124/dmd.31.5.645.
10
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.N,N'-二羟基脒:一种提高脒类口服生物利用度的新前药原理。
J Med Chem. 2007 Dec 27;50(26):6730-4. doi: 10.1021/jm701259d. Epub 2007 Dec 6.

引用本文的文献

1
Molybdenum's Role as an Essential Element in Enzymes Catabolizing Redox Reactions: A Review.钼作为参与氧化还原反应代谢酶的必需元素:综述。
Biomolecules. 2024 Jul 19;14(7):869. doi: 10.3390/biom14070869.
2
The History of mARC.mARC 的历史。
Molecules. 2023 Jun 12;28(12):4713. doi: 10.3390/molecules28124713.
3
Mitochondrial amidoxime-reducing component 2 (MARC2) has a significant role in -reductive activity and energy metabolism.线粒体酰羟肟酸还原酶成分 2(MARC2)在 -还原活性和能量代谢中具有重要作用。
J Biol Chem. 2019 Nov 15;294(46):17593-17602. doi: 10.1074/jbc.RA119.007606. Epub 2019 Sep 25.
4
Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes.人源 mARC1 的晶体结构揭示了其在真核钼酶中的特殊地位。
Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):11958-11963. doi: 10.1073/pnas.1808576115. Epub 2018 Nov 5.
5
CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer.CYB5R1与结直肠癌的上皮-间质转化及不良预后相关。
Oncotarget. 2016 May 24;7(21):31350-60. doi: 10.18632/oncotarget.8912.